Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Feb 12;12(1):120.
doi: 10.1186/s13287-021-02163-6.

JKAMP inhibits the osteogenic capacity of adipose-derived stem cells in diabetic osteoporosis by modulating the Wnt signaling pathway through intragenic DNA methylation

Affiliations

JKAMP inhibits the osteogenic capacity of adipose-derived stem cells in diabetic osteoporosis by modulating the Wnt signaling pathway through intragenic DNA methylation

Shuanglin Peng et al. Stem Cell Res Ther. .

Abstract

Background: Diabetic osteoporosis (DOP) is a systemic metabolic bone disease caused by diabetes mellitus (DM). Adipose-derived stem cells (ASCs) play an important role in bone regeneration. Our previous study confirmed that ASCs from DOP mice (DOP-ASCs) have a lower osteogenesis potential compared with control ASCs (CON-ASCs). However, the cause of this poor osteogenesis has not been elucidated. Therefore, this study investigated the underlying mechanism of the decline in the osteogenic potential of DOP-ASCs from the perspective of epigenetics and explored methods to enhance their osteogenic capacity.

Methods: The expression level of JNK1-associated membrane protein (JKAMP) and degree of DNA methylation in CON-ASCs and DOP-ASCs were measured by mRNA expression profiling and MeDIP sequencing, respectively. JKAMP small interfering RNA (siRNA) and a Jkamp overexpression plasmid were used to assess the role of JKAMP in osteogenic differentiation of CON-ASCs and DOP-ASCs. Immunofluorescence, qPCR, and western blotting were used to measure changes in expression of Wnt signaling pathway-related genes and osteogenesis-related molecules after osteogenesis induction. Alizarin red and ALP staining was used to confirm the osteogenic potential of stem cells. Bisulfite-specific PCR (BSP) was used to detect JKAMP methylation degree.

Results: Expression of JKAMP and osteogenesis-related molecules (RUNX2 and OPN) in DOP-ASCs was decreased significantly in comparison with CON-ASCs. JKAMP silencing inhibited the Wnt signaling pathway and reduced the osteogenic ability of CON-ASCs. Overexpression of JKAMP in DOP-ASCs rescued the impaired osteogenic capacity caused by DOP. Moreover, JKAMP in DOP-ASCs contained intragenic DNA hypermethylated regions related to the downregulation of JKAMP expression.

Conclusions: Intragenic DNA methylation inhibits the osteogenic ability of DOP-ASCs by suppressing expression of JKAMP and the Wnt signaling pathway. This study shows an epigenetic explanation for the reduced osteogenic ability of DOP-ASCs and provides a potential therapeutic target to prevent and treat osteoporosis.

Keywords: Adipose-derived stem cells; DNA methylation; Diabetic osteoporosis; JKAMP; Osteogenic differentiation; Wnt signaling pathway.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
JKAMP, the Wnt signaling pathway, and osteogenesis-related molecules are suppressed in DOP-ASCs. a Normal appearance passage 2 CON-ASCs and DOP-ASCs. b mRNA levels of Jkamp, Jnk1, β-catenin, Runx2, and Opn in CON-ASCs and DOP-ASCs. c Protein levels of JAKMP, Wnt signaling pathway-related molecules, and osteogenesis-related molecules in CON-ASCs and DOP-ASCs. Data represent the mean ± SD of at least three independent experiments, *P < 0.05, **P < 0.01
Fig. 2
Fig. 2
Si-Jkamp suppresses Wnt signaling and osteogenesis-related molecules in CON-ASCs (osteoinduction for 3 days). a, b Si-Jkamp downregulated the gene and protein levels of Wnt signaling pathway markers and osteogenesis-related molecules in CON-ASCs (osteoinduction for 3 days). Data represent the mean ± SD of at least three independent experiments, *P < 0.05, **P < 0.01
Fig. 3
Fig. 3
Si-Jkamp suppresses Wnt signaling and osteogenesis-related molecules in CON-ASCs (osteoinduction for 6 days). a, b mRNA and protein levels of Wnt signaling pathway markers and osteogenesis-related molecules were downregulated after si-Jkamp transfection into CON-ASCs (osteoinduction for 6 days). Data represent the mean ± SD of three or more independent experiments, *P < 0.05, **P < 0.01
Fig. 4
Fig. 4
Si-Jkamp decreases the osteogenic ability of CON-ASCs. a, b Immunofluorescence staining of RUX2 and OPN proteins in CON-ASCs after 3 days after osteoinduction. c Alizarin red staining of CON-ASCs after 14 days of osteoinduction. d, e ALP staining of CON-ASCs after 3 and 5 days of osteoinduction. d Osteoinduction for 3 days. e Osteoinduction for 5 days
Fig. 5
Fig. 5
Overexpression of Jkamp increases Wnt signaling and osteogenesis-related molecules in DOP-ASCs (osteoinduction for 3 days). a, b The Jkamp plasmid upregulated mRNA and protein levels of Wnt signaling pathway markers and osteogenesis-related molecules in DOP-ASCs (osteoinduction for 3 days). c DOP-ASCs cellular uptake of NC- plasmids and OE- plasmids after treated for 48 h. Data represent the mean ± SD of at least three independent experiments, *P < 0.05, **P < 0.01
Fig. 6
Fig. 6
Overexpression of Jkamp increases Wnt signaling and osteogenesis-related molecules in DOP-ASCs (osteoinduction for 6 days). a, b mRNA and protein levels of Wnt signaling pathway markers and osteogenesis-related molecules were upregulated after Jkamp plasmid transfection into DOP-ASCs (osteoinduction for 6 days). Data represent the mean ± SD of at least three independent experiments, *P < 0.05, **P < 0.01
Fig. 7
Fig. 7
Overexpression of Jkamp increases the osteogenic ability of DOP-ASCs. a, b Immunofluorescence staining of RUX2 and OPN proteins in DOP-ASC after 3 days of osteoinduction. c Alizarin red staining of DOP-ASCs after 14 days of osteoinduction. d, e ALP staining of DOP-ASCs after 3 and 5 days of osteoinduction. c Osteoinduction for 3 days. d Osteoinduction for 5 days
Fig. 8
Fig. 8
Increased methylation level of JKAMP in DOP-ASCs. a MeDIP sequencing showed that the intragenic methylation peaks of the JKAMP gene in DOP-ASCs were significantly higher than those in CON-ASCs. b Meth Primer software analysis showed that a large amount of CGI was enriched in the region near JKAMP exon 4 (genomic coordinates: chr12, 72093357–72094707). c, d BSP confirmed that the methylation degree of CON-ASCs was lower than that of matched DOP-ASCs in the region near exon 4 of JKAMP (genomic coordinates: chr12, 72093857–72094207). e Correlation between Jkamp mRNA levels and MeDIP peak enrichment near exon 4 of JKAMP (r2 = 0.977). Each data point corresponds to a high-throughput sequencing result, and the data were analyzed for correlation. Data represent the mean ± SD of at least three independent experiments, *P < 0.05, **P < 0.01

References

    1. Cho J, Scragg R, Petrov MS. Risk of mortality and hospitalization after post-pancreatitis diabetes mellitus vs type 2 diabetes mellitus: a population-based matched cohort study. Am J Gastroenterol. 2019;114(5):804–812. doi: 10.14309/ajg.0000000000000225. - DOI - PubMed
    1. Gilbert MP, Pratley RE. The impact of diabetes and diabetes medications on bone health. Endocr Rev. 2015;36(2):194–213. doi: 10.1210/er.2012-1042. - DOI - PubMed
    1. Shanbhogue VV, Hansen S, Frost M, Jorgensen NR, Hermann AP, Henriksen JE, Brixen K. Bone geometry, volumetric density, microarchitecture, and estimated bone strength assessed by HR-pQCT in adult patients with type 1 diabetes mellitus. J Bone Miner Res. 2015;30(12):2188–2199. doi: 10.1002/jbmr.2573. - DOI - PubMed
    1. Karim L, Bouxsein ML. Effect of type 2 diabetes-related non-enzymatic glycation on bone biomechanical properties. Bone. 2016;82:21–27. doi: 10.1016/j.bone.2015.07.028. - DOI - PMC - PubMed
    1. Khosla S, Shane E. A crisis in the treatment of osteoporosis. J Bone Miner Res. 2016;31(8):1485–1487. doi: 10.1002/jbmr.2888. - DOI - PubMed

Publication types

Substances